Description
NT-proBNP Fast Test Kit (Immunofluorescence Assay)
The NT-proBNP Fast Test Kit is a quantitative immunofluorescence assay designed for the rapid detection of N-terminal pro B-type natriuretic peptide (NT-proBNP) in human serum, plasma, or whole blood. With a quick 10-minute turnaround and high sensitivity, this test aids in the clinical diagnosis, prognosis, and risk stratification of heart failure (HF).
Key Advantages
- Rapid Testing: Results available in just 10 minutes
- High Sensitivity: Detects levels as low as ≤100 pg/mL
- Versatile Sample Types: Compatible with serum, plasma, and whole blood
- Wide Detection Range: 100–35,000 pg/mL
- Long Shelf Life: Stable for 24 months at 4–30°C
About NT-proBNP
NT-proBNP is a non-active N-terminal fragment released from the cleavage of BNP prohormone, secreted by the left ventricle in response to pressure and volume overload. It serves as a gold standard biomarker for the evaluation of heart failure. NT-proBNP also provides high sensitivity and negative predictive value, making it ideal for early detection and risk stratification in cardiac care.
Specifications
| Parameter | Details |
|---|---|
| Test Item | NT-proBNP |
| Sample Type | Plasma, Serum, Whole Blood |
| Detection Method | Immunofluorescence Assay |
| Detection Range | 100–35,000 pg/mL |
| Lower Detection Limit | ≤100 pg/mL |
| Test Time | 10 Minutes |
| Storage Conditions | 4–30°C |
| Shelf Life | 24 Months |
Compatible Devices
- Getein 1100 Immunofluorescence Quantitative Analyzer
- Getein 1160 Immunofluorescence Quantitative Analyzer
- Getein 1180 Immunofluorescence Quantitative Analyzer
- Getein 1200 Immunofluorescence Quantitative Analyzer
- Getein 1600 Immunofluorescence Quantitative Analyzer
- Getein 208 Hand-held Integrated System
Clinical Applications
- Gold standard for heart failure diagnosis and prognosis
- Early detection of heart failure
- Risk stratification and monitoring of heart failure
- Differentiation of heart failure from other causes of dyspnea
- Evaluation of treatment effectiveness in HF management
- Risk stratification in acute coronary syndromes (ACS)
